The classics in perspective

Gut. 2007 Sep;56(9):1184-6. doi: 10.1136/gut.2007.121830.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adalimumab
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Certolizumab Pegol
  • Crohn Disease / drug therapy*
  • Crohn Disease / immunology
  • Drug Therapy, Combination
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Immunoglobulin Fab Fragments / adverse effects
  • Immunoglobulin Fab Fragments / therapeutic use
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Infliximab
  • Polyethylene Glycols / adverse effects
  • Polyethylene Glycols / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • Immunoglobulin Fab Fragments
  • Immunologic Factors
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Polyethylene Glycols
  • Infliximab
  • Adalimumab
  • Certolizumab Pegol